Camson Bio Technologies Limited reported audited standalone earnings results for the fourth quarter and standalone and consolidated earnings results for the year ended March 31, 2017. For the quarter, on standalone basis, revenue from operations was INR 7.235 million against negative of INR 56.345 million a year ago. Loss before tax and exceptional item and loss before tax was INR 114.188 million against INR 297.911 million a year ago. Loss was INR 113.046 million or INR 3.77 per basic and diluted share against INR 270.151 million or INR 9.01 per basic and diluted share a year ago. For the year, on standalone basis, revenue from operations was INR 103.502 million against INR 254.033 million a year ago. Loss before tax and exceptional item and loss before tax was INR 273.741 million against INR 399.278 million a year ago. Loss was INR 272.036 million or INR 9.07 per basic and diluted share against INR 378.348 million or INR 12.61 per basic and diluted share a year ago. For the year, on consolidated basis, revenue from operations was INR 153.923 million against INR 621.153 million a year ago. Loss before tax and exceptional item was INR 292.395 million against INR 435.104 million a year ago. Loss before tax was INR 321.593 million against INR 435.104 million a year ago. Loss for the year was INR 319.888 million or INR 11.31 per basic and diluted share against INR 414.226 million or INR 1.07 per basic and diluted share a year ago.